BioLineRX Ltd. · TASE:BLRX

BioLineRX — Investor Presentation (October 2018)

30 slides from BioLineRX's investor presentation, Oct 1, 2018

  1. Slide 1: Transforming science into medicine

    Slide 1: Transforming science into medicine

    Transforming science into medicine

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    2 Forward-looking statements This presentation contains “forward-looking statements.” These statements include words like “may,” “expects,” “believes,” “plans,” “scheduled,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and

  3. Slide 3: Our Mission

    Slide 3: Our Mission

    3 Our Mission Our mission is to become a leader in the development of novel therapeutics for the treatment of cancer

  4. Slide 4: Who Are We?

    Slide 4: Who Are We?

    4 Who Are We? Ticker / Exchange BLRX (NASDAQ) Headquarters Tel Aviv, Israel Market cap ~$140 million (1-Oct-18) Shares outstanding ~108 million Cash ~$41.1 million (30-Jun-18) Cash runway Through 1H 2020 Employees ~55 (~40 in R&D) NASDAQ: BRLX

  5. Slide 5: Investment Highlights

    Slide 5: Investment Highlights

    5 Investment Highlights ➢ Large-market indications with unmet medical needs Singular focus on ➢ Phase 3: stem cell mobilization oncology ➢ Phase 2: AML, pancreatic, gastric ➢ Nine mid-to-late stage studies ongoing Multiple opportunities ➢ 3-4 data readouts over next 12 months for value creation ➢ Ph

  6. Slide 6: Leadership Team

    Slide 6: Leadership Team

    6 Leadership Team Seasoned executives with decades of experience in medicine, drug development, clinical studies, and financial and corporate development Philip A. Serlin, CPA, MBA Chief Executive Officer Mali Zeevi, CPA Chief Financial Officer Hillit Mannor Shachar, MD, MBA, VP of Business Developm

  7. Slide 7: A Diverse Pipeline Targeting Multiple Oncology Indications

    Slide 7: A Diverse Pipeline Targeting Multiple Oncology Indications

    7 A Diverse Pipeline Targeting Multiple Oncology Indications REGULATORY PROJECT INDICATION PRE-CLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL CANCER BL-8040 Stem-cell mobilization Relapsed/refractory AML Consolidation AML Maintenance AML Gastric cancer Non-small cell lung cancer Pancreatic cancer Pancrea

  8. Slide 8: BL-8040 – Best-In-Class CXCR4 Antagonist for Multiple Oncology and Hematology Indications

    Slide 8: BL-8040 – Best-In-Class CXCR4 Antagonist for Multiple Oncology and Hematology Indications

    BL-8040 – Best-In-Class CXCR4 Antagonist for Multiple Oncology and Hematology Indications For treatment of solid tumors, AML and indications requiring hematopoietic stem cell transplantation

  9. Slide 9: BL-8040 – A Best-in-Class CXCR4 Antagonist Targeting Multiple Indications

    Slide 9: BL-8040 – A Best-in-Class CXCR4 Antagonist Targeting Multiple Indications

    9 BL-8040 – A Best-in-Class CXCR4 Antagonist Targeting Multiple Indications A 14-amino acid synthetic cyclic peptide, high-affinity CXCR4 antagonist with long receptor occupancy (>48 hours) and extended CXCR4 inhibition Phase 3 Phase 2 Phase 1 & 2 Stem Cell Mobilization Acute Myeloid Leukemia Cancer

  10. Slide 10: Stem Cell Mobilization

    Slide 10: Stem Cell Mobilization

    10 Stem Cell Mobilization BL-8040 in Stem Cell Mobilization

  11. Slide 11: Stem-Cell Mobilization For Patients Undergoing Bone-Marrow Transplantation

    Slide 11: Stem-Cell Mobilization For Patients Undergoing Bone-Marrow Transplantation

    11 Stem-Cell Mobilization For Patients Undergoing Bone-Marrow Transplantation Patients with hematological malignancies often require HSC transplant after treatment to restore their immune system Significant unmet medical need in SCM • Multiple apheresis sessions required • 50-70% of patients are poo

  12. Slide 12: GENESIS Phase 3 Study: Mobilization of HSCs in Multiple Myeloma Patients

    Slide 12: GENESIS Phase 3 Study: Mobilization of HSCs in Multiple Myeloma Patients

    12 GENESIS Phase 3 Study: Mobilization of HSCs for Autologous Transplant in Multiple Myeloma Patients Initiated Q4 2017 - Phase 3 randomized, placebo-controlled, safety and efficacy study (n=177): NCT03246529 Study design BL-8040 potentially offers patients: Part 1: Lead-in period - dose confirmatio

  13. Slide 13: BL-8040 in AML

    Slide 13: BL-8040 in AML

    BL-8040 in AML BIOLINEM>X<

  14. Slide 14: BL-8040's Potential Role in the AML Treatment Pathway

    Slide 14: BL-8040's Potential Role in the AML Treatment Pathway

    14 BL-8040’s Potential Role in the AML Treatment Pathway – Sensitizing Leukemic Cells to Anti-Cancer Therapies Malignant cells are harbored within protected niches in the bone marrow (minimal residual disease), which impacts remission and survival rates BL-8040 mobilizes AML cells to the peripheral

  15. Slide 15: BL-8040.01 Phase 1/2a Study in Relapsed/Refractory AML

    Slide 15: BL-8040.01 Phase 1/2a Study in Relapsed/Refractory AML

    15 BL-8040.01 Phase 1/2a Study: Encouraging Results in Patients with Relapsed/Refractory AML Phase 1/2a dose escalation/expansion study (n=42): NCT01838395 Study design Comparison of the composite response rate Dose escalation (0.5 to 2.0 mg/kg) with expansion cohort at 1.5mg/kg (CR + CRi) of BL-804

  16. Slide 16: BLAST Phase 2b Study: Consolidation Therapy for AML

    Slide 16: BLAST Phase 2b Study: Consolidation Therapy for AML

    16 BLAST Phase 2b Study: Consolidation Therapy for AML Patients in First Remission Phase 2b double-blind, multi-center placebo controlled study (n=194): NCT02502968 Treatment: Two or three cycles (age-based) of high-dose Ara-C in combination with either BL-8040 or placebo Endpoints BL-8040 potential

  17. Slide 17: BL-8040 in Cancer Immunotherapy

    Slide 17: BL-8040 in Cancer Immunotherapy

    BL-8040 in Cancer Immunotherapy

  18. Slide 18: BL-8040 – Addressing Unmet Needs in Cancer Immunotherapy

    Slide 18: BL-8040 – Addressing Unmet Needs in Cancer Immunotherapy

    18 BL-8040 – Addressing Unmet Needs in Cancer Immunotherapy Despite significant advances in cancer BL-8040 addresses these needs by: immunotherapy, material needs remain: Improving efficacy of immunotherapy in Mobilizing immune cells to peripheral blood “cold” tumors, such as pancreatic cancer circu

  19. Slide 19: Data Supporting Role of BL-8040 in Immunotherapy

    Slide 19: Data Supporting Role of BL-8040 in Immunotherapy

    19 Data Supporting Role of BL-8040 in Immunotherapy Robust mobilization Tumor infiltration1 Microenvironment modification Pre-treatment Healthy volunteers were treated with CXCR4 antagonism selectively inhibits BL-8040 or placebo the migration of immunosuppressive cells Single administration of BL-8

  20. Slide 20: Ongoing Collaborations with Global Pharma Companies Validate BL-8040

    Slide 20: Ongoing Collaborations with Global Pharma Companies Validate BL-8040

    20 Ongoing Collaborations with Global Pharma Companies Validate BL-8040’s Novel Mechanism of Action NCT02826484, NCT03193190, NCT03281369, NCT03154827 COMBAT Phase 2a study for BL-8040 + Four phase 1/2 studies planned for BL-8040 + pembrolizumab (Keytruda®) atezolizumab (TecentriqTM) Study in metast

  21. Slide 21: COMBAT Phase 2a Study in Advanced Pancreatic Cancer

    Slide 21: COMBAT Phase 2a Study in Advanced Pancreatic Cancer

    21 COMBAT Phase 2a Study in Advanced Pancreatic Cancer Phase 2a open-label, multi-center study in combination with pembrolizumab (n=37): NCT02826484 To assess the safety and efficacy of BL-8040 in combination with pembrolizumab (Keytruda) in patients with advanced pancreatic cancer Endpoints Interme

  22. Slide 22: AGI-134 – Cancer Immunotherapy

    Slide 22: AGI-134 – Cancer Immunotherapy

    AGI-134 – Cancer Immunotherapy A universal anti-cancer vaccine with a unique mechanism of action

  23. Slide 23: Alpha-Gal and Anti-Gal

    Slide 23: Alpha-Gal and Anti-Gal

    23 Alpha-Gal and Anti-Gal The alpha-Gal epitope is abundantly synthesized on glycolipids of non-primates while absent in human Due to constant exposure to this antigen (expressed by gut flora) humans develop and maintain high levels of anti-Gal Abs Xenotransplantation experiments in the 1980’s-90’s

  24. Slide 24: AGI-134 Induces a Potent Patient-Specific Anti-Tumor Immune Response

    Slide 24: AGI-134 Induces a Potent Patient-Specific Anti-Tumor Immune Response

    24 AGI-134 Induces a Potent Patient-Specific Anti-Tumor Immune Response AGI-134 is being developed to realize the therapeutic potential of alpha-Gal/anti-Gal immunology ▪ Tumors vary from patient to patient in their neoantigen load and identity ▪ AGI-134 is a fully synthetic alpha-Gal glycolipid mol

  25. Slide 25: AGI-134 Induces Regression of Established Melanoma Tumors in Mice

    Slide 25: AGI-134 Induces Regression of Established Melanoma Tumors in Mice

    25 Intratumoral Treatment with AGI-134 Induces Regression of Established Melanoma Tumors in Mice Administration of AGI-134 induced regression of established primary tumors Days post inoculation ASCO-SITC 2018 Abstract 68 / poster E4

  26. Slide 26: AGI-134 Exerts a Potent Durable Abscopal Effect

    Slide 26: AGI-134 Exerts a Potent Durable Abscopal Effect

    26 AGI-134 Exerts a Potent Durable Abscopal Effect Single dose of AGI-134 into primary tumor protected mice from secondary tumor development for more than 90 days Synergistic effect demonstrated in combination of AGI-134 with immune checkpoint inhibitor Inoculate melanoma cells Treat 1° tumor Monito

  27. Slide 27: Outline of Ongoing Phase 1/2a Clinical Study of AGI-134

    Slide 27: Outline of Ongoing Phase 1/2a Clinical Study of AGI-134

    High Level Outline of Ongoing Phase 1/2a Clinical Study AGI-134 27 Open-label study to evaluate the safety and tolerability of AGI-134 as monotherapy and in combination with AGI-134+ICI pembrolizumab, in unresectable metastatic solid tumors (NCT03593226) PART 1 PART 2 Accelerated escalation monother

  28. Slide 28: Looking ahead

    Slide 28: Looking ahead

    Looking ahead BIOLINEP>*<

  29. Slide 29: Recent Accomplishments and Upcoming Milestones

    Slide 29: Recent Accomplishments and Upcoming Milestones

    29 Recent Accomplishments and Upcoming Milestones Multiple opportunities for value creation BL-8040 Partial results from Phase 2a COMBAT pancreatic cancer study (with Merck) 1Q 2018 BL-8040 Top-line results from Phase 2 allogenic stem cell mobilization (Auto SCM) study 2Q 2018 AGI-134 Initiation of

  30. Slide 30: Key Takeaways

    Slide 30: Key Takeaways

    30 Key Takeaways ➢ Large-market indications with unmet medical needs Singular focus on ➢ Phase 3: stem cell mobilization oncology ➢ Phase 2: AML, pancreatic, gastric ➢ Nine mid-to-late stage studies ongoing Multiple opportunities ➢ 3-4 data readouts over next 12 months for value creation ➢ Phase 3 r

Source: Internet Archive copy of biolinerx.com

More decks from BioLineRX Ltd.

All 37 BioLineRX decks